1Q Revenues: $10.9 billion (-8%)
1Q Earnings: $2.7 billion (-2%)
Comments: U.S. revenues were $5.0 billion (-10%) and International revenues were $5.9 billion (-7%). Foreign exchange unfavorably impacted revenues by approximately 5%. Results were impacted by loss of U.S. exclusivity for Zyrtec in January 2008 and Camptosar in February 2008, revenue declines for Lipitor and Chantix, as well as costs incurred in connection with the pending Wyeth acquisition. Oncology revenues were $350 million (-17%). Lipitor sales were down 13% to $2.7 billion and Chantix sales were down 36% to $177 million, impacted by revised labeling warnings. Lyrica sales were $684 million (+17%).